The Global Lateral Flow Assays Market in terms of revenue was estimated to be worth $10.8 billion in 2023 and is poised to reach $16.8 billion by 2029, growing at a CAGR of 7.6% from 2023 to 2029. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The rising adoption of kits reagents and lateral flow assay readers for infectious diseseas testing, veterinary diagnostics, and drug of abuse testing, cardiac marker testing. Whereas most of lateral flow assays are having limitation of qualitative detection, lot to lot variation like factors may hinder the growth of market during the forecast period.

Download an Illustrative overview:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=167205133

Browse in-depth TOC on "Lateral Flow Assays Market"

420 - Tables

59 - Figures

399 – Pages

Lateral Flow Assays Market Dynamics

Driver: Increase in eye disorders

Age is the major factor in eye related disorder. The rise in population and increase in chronic exposure to UV screens are influencing the rise in eye-related disorders. The most common diseases include diabetic retinopathy, glaucoma, cataract, corneal opacities, Trachoma, refractive error disease, etc. The rise of diabetic retinopathy, a prevalent challenge for many living with diabetes, has ignited a demand for advanced imaging and laser treatments. These advancements, along with innovative technologies like femtosecond lasers and phacoemulsification systems for cataracts, represent a beacon of hope in the global fight against vision loss. This isn't just a story of market forces; it's a testament to the power of scientific progress in empowering us to protect our precious eyesight. As awareness grows and preventive measures take hold, the need for specialized lateral flow assays is likely to remain strong, fueled by both the apprehension of losing sight and the unwavering desire to preserve it. In North America, there is an estimate that nearly 56 million people will be affected from diabetic retinopathy and will reach 63.2 million. (Source: IDF). On the other hand, according to NIH 2020, approximately 10 million cataract operations are performed every year in the world, with rates varying from 100 to 6000 operations per million population per year. According to the National Eye Institute, about 200,000 new cases of wet AMD are diagnosed each year in North America.

Restraint: rising adoption of previously owned equipments

The market includes a lot of local players that tend to provide refurbished equipment at cost-effective prices. Since the cost associated with this equipment is touching the sky, these local players have gained a large momentum in the past. The true reasons for the adoption of refurbished equipments include

First of all, healthcare is becoming increasingly cost-conscious. A growing number of organizations and individual practitioners are looking for more affordable options due to budgetary restrictions and rising equipment costs. Refurbished equipment can provide equivalent performance and reliability to new equipment, which makes it an appealing alternative because it is sometimes much less expensive. Second, improvements in refurbishing technology are making reconditioned equipment last longer and be of higher quality. Reputable refurbishers may guarantee performance that satisfies exacting medical requirements with careful cleaning, recalibration, and replacement of worn parts. Healthcare providers find used equipment more appealing due to its increased reliability. Thirdly, a move towards sustainable practices is being driven by environmental concerns. Refurbishing equipment contributes to waste reduction and equipment longevity, which is in line with the increasing demand for ethical healthcare practices. Thus, the refurbished market is creating a huge barrier for growth.

Opportunity: Low adoption of phacoemulsification devices and premium IOLs in emerging regions

Phacoemulsification is regarded as an important and effective treatment in treating cataract surgeries. It involves the removal of lens by breaking it. It makes cataract surgery safe and effective, and used nearly 60% of the time to treat cataracts of which only 25% is used in Asia. In India, nearly 17% of cataract surgeries are done using this technique and premium lenses are used in only 8% of these surgeries. Reduced reimbursement for use of such high priced lenses and high post operative costs are reasons of low adoption in emerging regions. Thus, it is said that premium lenses at cost effective price would represent a huge market potential in merging regions creating opportunities for growth in the Asia Pacific region and Latin America region. The cost of phacoemulsification equipment and high-end IOLs is much more than that of conventional cataract surgery methods. Basic care is prioritized in settings with limited resources, therefore it might be difficult to justify the increased cost of these cutting-edge devices.

Phacoemulsification implementation necessitates operating rooms, specialized equipment, and skilled staff. Lack of these resources prevents widespread adoption in many growing regions. Furthermore, teaching surgeons these intricate methods can be costly and time-consuming. The advantages of high-end IOLs, such as better vision quality and less need for glasses, may not be well recognized or appreciated in areas where basic vision restoration is the main issue. Driving the adoption of these technologies requires educating patients and creating awareness of their benefits.

Challenge: Lack of skilled professionals

The demand for skilled professionals is high, and the actual numbers don’t justify it. This was initially an issue in the emerging regions however it is holding true in the mature markets as well. This leads to a lack of adoption of technologically advanced tools and in turn hampers market growth. As per the All India Ophthalmic Society, in 2019, only 15,000 professionals in the ophthalmology space were treating 1 to 100,000 people. Similarly, in 2021, the American Academy of Ophthalmologists reported 18,000 practicing ophthalmologists in the US only. In the sub Saharan Africa there is an average of 2.5 ophthalmologists for every million patients. Similarly, in China it is 44,000 doctors and only 1.6 doctors for every 50,000 people. Thus, it creates hindrance in the adoption of the improved technology and the user is not skilled enough.

Request Sample Pages:

https://www.marketsandmarkets.com/requestsampleNew.asp?id=167205133

The rising  demand of lateral flow assays due to increasing  number of geriatric population, growing prevalence of infectious diseases as well as increasing of of point of care tests are some of the key factors that are driving the growth of this market. However , the hesitance in the patients as awell as in health professionals to change in the conventional diagnostic method  and the lack of  accuracy of lateral flow assays are some of the key restraints for lateral flow assyas market

In this report, the lateral flow assays market is segmented on the basis of product type, application type, technique type, sample type, end user, and region.

“Kits and Reagents segment is expected to witness the highest growth during the forecast period”

Based on product type, the lateral flow assays market is segmented into kits reagents and lateral flow readers. During the forecast period, the the lateral flow readers segment is expected to witness the second highest growth during the forecast period. The growth of this segment can be attributed as these are economical, quantitative as well as capability of assaying multiple analytes simultaneously.

“Veterinary Diagnostic segment accounted for the second largest share of lateral flow assays market in 2022”

Based on applications, the lateral flow assays market is segmented into clinical testing, veterinary diagnostics, food safety environmental testing, and drug development quality testing. The veterinary diagnostic segment accounted for the second largest share of the lateral flow assays market in 2022.In the veterinary diagnostic segment, lateral flow tests are used to test commercial livestock and household pets for various medical conditions, including bacterial and viral infections, allergies, fertility issues, and diabetes. The possibility of infectious disease outbreaks (particularly in large livestock animals) drives the demand for lateral flow tests due to their simplicity and rapidity compared to conventional detection methods.

“The multiplex detection assays technique is expected to witness the fastest growth during the forecast period”

Based on technique, the lateral flow assay kits reagents market is segmented into competitive assays, sandwich assays, and multiplex detection assays. The multiplex detection assays technique anticipated to undergo the most substantial growth in the given forecast period. The multiplex assays are useful in clinical diagnosis as it allows to help and decide the stage of a disease where multiple interdependent analytes are involved in the test process. It is highly desirable to analyze multiple analytes simultaneously under the same set of conditions.

Key Market Players :

The key players in the global lateral flow assays market include Abbott Laboratories (US), Quidel Corporation (US), F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US), Siemens AG (Germany), BD (US), bioMérieux SA (France), Thermo Fisher Scientific, Inc. (US),and PerkinElmer Inc. (US).

North America is expected to account for the largest share of the lateral flow assays industry.

North America has some of the highest worldwide healthcare spending rates, which translates into large investments in state-of-the-art ophthalmic technology. This encourages the creation and uptake of cutting-edge technology, expanding the realm of what is practical for preventive and vision restoration. World-class research facilities and medical centers that are at the forefront of ocular research and development can be found in the area. This creates a vibrant ecosystem that encourages innovation, which results in a steady supply of new and enhanced equipment coming to market. Naturally, as North America's population ages, age-related eye conditions like cataracts and macular degeneration become more common. Growth is further accelerated as a result of the expanded market for diagnostic and therapeutic equipment.

Recent Developments of Lateral Flow Assays Industry:

• In August 2023, Quidelortho received authorization from the US Food and Drug Administration (FDA), allowing the company to market its new Sofia 2 SARS Antigen+ FIA.
• In February 2022, Abbott Laboratories received FDA Emergency Use Authorization (EUA) for its Alinity M assay to detect antibodies to SARS-CoV-2.
• In October 2022, Roche launched the next-generation portfolio of SARS-CoV-2 rapid antigen tests (“2.0”).

Get 10% Free Customization on this Report:

https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=167205133

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: [email protected]

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/lateral-flow-assay-market.asp

Content Source: https://www.marketsandmarkets.com/PressReleases/lateral-flow-assay.asp